These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14694005)

  • 1. Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes.
    Burge MR; Carey JD
    Diabetes Care; 2004 Jan; 27(1):275-6. PubMed ID: 14694005
    [No Abstract]   [Full Text] [Related]  

  • 2. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?
    Ampudia-Blasco FJ; Hasbum B; Carmena R
    Diabetes Care; 2003 Mar; 26(3):953-4. PubMed ID: 12610070
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic decompensation in pump users due to lispro insulin precipitation.
    Wolpert HA; Faradji RN; Bonner-Weir S; Lipes MA
    BMJ; 2002 May; 324(7348):1253. PubMed ID: 12028980
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause?
    Griffin ME; Feder A; Tamborlane WV
    Diabetes Care; 2001 Jan; 24(1):174. PubMed ID: 11194227
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of lipoatrophy with Lispro insulin without insulin pump therapy.
    Arranz A; Andia V; López-Guzmán A
    Diabetes Care; 2004 Feb; 27(2):625-6. PubMed ID: 14747261
    [No Abstract]   [Full Text] [Related]  

  • 6. Glargine and lispro: two cases of mistaken identity.
    Adlersberg MA; Fernando S; Spollett GR; Inzucchi SE
    Diabetes Care; 2002 Feb; 25(2):404-5. PubMed ID: 11815523
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
    Thrasher J; Surks H; Nowotny I; Pierre S; Rotthaeuser B; Wernicke-Panten K; Garg S
    J Diabetes Sci Technol; 2018 May; 12(3):680-686. PubMed ID: 29359575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Continuous subcutaneous insulin infusion].
    Ito H; Kanatsuka A
    Nihon Rinsho; 1997 Nov; 55 Suppl():267-72. PubMed ID: 9434479
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus.
    Szypowska A; Skórka A; Pańkowska E
    Pediatr Endocrinol Diabetes Metab; 2008; 14(2):117-8. PubMed ID: 18721499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.
    Radermecker RP; Piérard GE; Scheen AJ
    Am J Clin Dermatol; 2007; 8(1):21-8. PubMed ID: 17298103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion. A case report.
    Meier M; Brand J; Standl E; Schnell O
    Diabetes Care; 1998 Jul; 21(7):1044-5. PubMed ID: 9653592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe insulin resistance treated with insulin lispro.
    Gill G; Williams G
    Lancet; 1997 Jan; 349(9046):211. PubMed ID: 9111571
    [No Abstract]   [Full Text] [Related]  

  • 15. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog).
    Roper NA; Bilous RW
    Diabet Med; 1998 Dec; 15(12):1063-4. PubMed ID: 9868982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On calculating treatment satisfaction.
    Bradley C
    Diabetes Care; 1999 Oct; 22(10):1760. PubMed ID: 10526762
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe Hypoglycemia Before Landing in a Patient with Type 1 Diabetes Using Sensor-Augmented Pump Therapy.
    Viñals C; Pané A; Quirós C; Giménez M; Conget I
    Diabetes Technol Ther; 2017 Aug; 19(8):491-492. PubMed ID: 28594566
    [No Abstract]   [Full Text] [Related]  

  • 18. A Single-Center Long-Term Continuous Subcutaneous Insulin Infusion (CSII) Experience: Higher Fractional Use Is Associated With Less Diabetes Complications.
    Tubili C; Folco UD; Nardone MR; Clementi A
    J Diabetes Sci Technol; 2017 Sep; 11(5):1057-1058. PubMed ID: 28367635
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR; Bell MA; Heyob JA; Storms SM
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin desensitization with insulin lispro and an insulin pump in a 5-year-old child.
    Eapen SS; Connor EL; Gern JE
    Ann Allergy Asthma Immunol; 2000 Nov; 85(5):395-7. PubMed ID: 11101184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.